GlassScriptPhysician profile
Aliya Yamin
NPI 1649342528
$2,370.14
in general payments reported to CMS, 2019-2025
26 companies · $1,049 in 2025
The $1,049 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $355 · 2020: $173 · 2021: $61.27 · 2022: $156 · 2023: $158 · 2024: $417 · 2025: $1,049.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,625.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,624.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $319.11 | 2024-2025 | |
| Novo Nordisk INC | $301.21 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $299.86 | 2019-2021 | |
| Lilly USA, LLC | $221.93 | 2020-2025 | Zepbound, Mounjaro |
| Abbvie INC. | $206.50 | 2021-2025 | |
| Glaxosmithkline, LLC. | $155.47 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbott Laboratories | $139.84 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Dexcom, INC. | $107.91 | 2022-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $95.83 | 2019-2025 | Airsupra, Farxiga |
| Astellas Pharma US INC | $69.70 | 2023-2025 | Veozah |
| Medtronic, INC. | $47.56 | 2024-2025 | Intellis Adaptivestim, Venaseal |
| Merck Sharp & Dohme LLC | $47.37 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $41.55 | 2024 | |
| Amarin Pharma, INC. | $36.43 | 2019 | |
| Boston Scientific Corporation | $33.78 | 2025 | General - Pain Management |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $33.27 | 2025 | Auvelity, Symbravo |
| Exact Sciences Corporation | $30.47 | 2025 | Cologuard Collection Kit |
| Allergan, INC. | $30.35 | 2019-2020 | |
| Shield Therapeutics INC | $26.40 | 2025 | |
| Dynavax Technologies Corporation | $24.76 | 2025 | Heplisav-B |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.66 | 2019 | |
| Idorsia Pharmaceuticals US INC | $18.01 | 2023 | Quviviq |
| Genentech USA, INC. | $17.32 | 2019 | |
| Lifescan, INC. | $16.98 | 2022 | |
| Sumitomo Pharma America, INC. | $16.70 | 2025 | Gemtesa |
| Gilead Sciences, INC. | $13.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aliya Yamin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.